lutetium

Summary

Summary: Lutetium. An element of the rare earth family of metals. It has the atomic symbol Lu, atomic number 71, and atomic weight 175.

Top Publications

  1. ncbi 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer
    Laura E Lantry
    Ernst Felder Laboratories, Bracco Research USA Inc, Princeton, New Jersey 08540 6608, USA
    J Nucl Med 47:1144-52. 2006
  2. ncbi [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy
    M De Jong
    Department of Nuclear Medicine, University Hospital and Erasmus University Rotterdam, 3015 GD Rotterdam, The Netherlands
    Int J Cancer 92:628-33. 2001
  3. ncbi Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors
    Hanwen Zhang
    Division of Radiological Chemistry, Institute of Nuclear Medicine, Department of Radiology, University Hospital, Basel
    Cancer Res 64:6707-15. 2004
  4. doi Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging
    Alexander B Stillebroer
    Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Nucl Med 53:82-9. 2012
  5. ncbi Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate
    Jaap J M Teunissen
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Clin Oncol 22:2724-9. 2004
  6. ncbi Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma
    F Forrer
    Institute of Nuclear Medicine, University Hospital of Basel, Basel, Switzerland
    Q J Nucl Med Mol Imaging 52:334-40. 2008
  7. pmc Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
    Bart de Keizer
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 35:749-55. 2008
  8. doi 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy
    Michael Garkavij
    Department of Oncology, Lund University and Lund University Hospital, Lund, Sweden
    Cancer 116:1084-92. 2010
  9. ncbi Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer
    Anneli Schmitt
    Department of Radiation Physics, Lundberg Laboratory for Cancer Research, Goteborg University, Sahlgrenska University Hospital, Goteborg, Sweden
    Cancer Biother Radiopharm 18:593-9. 2003
  10. ncbi [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients
    D J Kwekkeboom
    Department of Nuclear Medicine, University Hospital Rotterdam, The Netherlands
    Eur J Nucl Med 28:1319-25. 2001

Research Grants

  1. Low Cost Lu-based Scintillator Crystals for PET Scanners
    WESLEY HACKENBERGER; Fiscal Year: 2004
  2. Production of High Specific Activity Lutetium-177
    Cathy Cutler; Fiscal Year: 2005
  3. Optical Ceramic Hafnates: New Fast PET Scintillator
    Charles Brecher; Fiscal Year: 2006
  4. Time-of-flight PET for Improved whole-body imaging
    Joel S Karp; Fiscal Year: 2010
  5. Lanthanides as Novel Anti-Arthritic Agents
    Christopher Evans; Fiscal Year: 2004
  6. Metallofullerene Nanoplatform for Imaging & Treatment
    Panos Fatouros; Fiscal Year: 2009
  7. Synthesis via Metal-Catalyzed and Cationic Cyclizations
    THOMAS STUART LIVINGHOUSE; Fiscal Year: 2010
  8. Synthesis via Metal-Catalyzed and Cationic Cyclizations
    THOMAS LIVINGHOUSE; Fiscal Year: 2007
  9. A Positron Emission Mammography/Tomography Biopsy Device
    RAYMOND RAYLMAN; Fiscal Year: 2006
  10. BIOMEDICAL APPLICATIONS OF EXPANDED PORPHYRINS
    Jonathan Sessler; Fiscal Year: 2004

Detail Information

Publications196 found, 100 shown here

  1. ncbi 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer
    Laura E Lantry
    Ernst Felder Laboratories, Bracco Research USA Inc, Princeton, New Jersey 08540 6608, USA
    J Nucl Med 47:1144-52. 2006
    ..We describe a new radiolabeled bombesin (BBN) analog for imaging and systemic radiotherapy that has improved pharmacokinetics (PK) and better retention of radioactivity in the tumor...
  2. ncbi [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy
    M De Jong
    Department of Nuclear Medicine, University Hospital and Erasmus University Rotterdam, 3015 GD Rotterdam, The Netherlands
    Int J Cancer 92:628-33. 2001
    ..This candidate molecule shows great promise for radionuclide therapy in patients with sst(2)-expressing tumors...
  3. ncbi Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors
    Hanwen Zhang
    Division of Radiological Chemistry, Institute of Nuclear Medicine, Department of Radiology, University Hospital, Basel
    Cancer Res 64:6707-15. 2004
    ..The aim of this study was to develop radiolabeled (Indium-111, Lutetium-177, and Yttrium-90) bombesin analogues with affinity to the three bombesin receptor subtypes for targeted ..
  4. doi Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging
    Alexander B Stillebroer
    Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Nucl Med 53:82-9. 2012
    ..The estimated radiation doses were correlated with observed hematologic toxicity. In addition, the accuracy of the predicted therapeutic absorbed doses, based on diagnostic (111)In-cG250 data, were determined...
  5. ncbi Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate
    Jaap J M Teunissen
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Clin Oncol 22:2724-9. 2004
    ..To evaluate the quality of life (QoL) in patients with metastatic somatostatin receptor positive gastroenteropancreatic tumors treated with [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-octreotate) therapy...
  6. ncbi Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma
    F Forrer
    Institute of Nuclear Medicine, University Hospital of Basel, Basel, Switzerland
    Q J Nucl Med Mol Imaging 52:334-40. 2008
    ..We evaluated the effectiveness and toxicity of radiolabeled DOTATOC in patients with metastatic paraganglioma and pheochromocytoma...
  7. pmc Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
    Bart de Keizer
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 35:749-55. 2008
    ..The aim of this study was to investigate the incidence of hormonal crises after therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-octreotate)...
  8. doi 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy
    Michael Garkavij
    Department of Oncology, Lund University and Lund University Hospital, Lund, Sweden
    Cancer 116:1084-92. 2010
    ..In commonly used dosimetry methods, planar imaging is used for determination of the residence time, whereas the kidney mass is determined from a computed tomography (CT) scan...
  9. ncbi Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer
    Anneli Schmitt
    Department of Radiation Physics, Lundberg Laboratory for Cancer Research, Goteborg University, Sahlgrenska University Hospital, Goteborg, Sweden
    Cancer Biother Radiopharm 18:593-9. 2003
    ..In this study the biodistribution of a somatostatin analogue, (177)Lu-[DOTA(0),Tyr(3)]octreotate, was investigated in an animal model, as a possible therapeutic radiopharmaceutical...
  10. ncbi [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients
    D J Kwekkeboom
    Department of Nuclear Medicine, University Hospital Rotterdam, The Netherlands
    Eur J Nucl Med 28:1319-25. 2001
    ..Also, labelled with the beta- and gamma-emitting radionuclide lutetium-177, this compound has been shown to have a very favourable impact on tumour regression and animal survival in a ..
  11. doi Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1
    Christina Swärd
    The Lundberg Laboratory for Cancer Research, Sahlgrenska University Hospital, Goteborg, Sweden
    Cancer Biother Radiopharm 23:114-20. 2008
    ..Octreotate seems to be a more suitable somatostatin analog than octreotide for receptor-mediated radiation therapy. P-CgA is a simple, accurate method for the estimation of tumor response in this animal model...
  12. doi Absolute peptide quantification by lutetium labeling and nanoHPLC-ICPMS with isotope dilution analysis
    Christina Rappel
    Laboratoire de Chimie Analytique Bio Inorganique et Environnement, CNRS UMR 5254, Helioparc, 2 av Pr Angot, F 64053 Pau, France
    Anal Chem 81:385-93. 2009
    ..work, a novel approach was developed for accurate absolute peptide quantification based on metal labeling with lutetium diethylenetriamine pentaacetic acid (Lu-DTPA) and nanoflow high-performance liquid chromatography-inductively ..
  13. pmc Lutetium-labelled peptides for therapy of neuroendocrine tumours
    B L R Kam
    Department of Nuclear Medicine, Erasmus MC, s Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 39:S103-12. 2012
    ..If more widespread use of PRRT can be guaranteed, such therapy may well become the therapy of first choice in patients with metastasized or inoperable neuroendocrine tumours...
  14. ncbi Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides
    William H Miller
    Nuclear Science and Engineering Institute, University of Missouri, Columbia, MO 65211, USA
    Cancer Biother Radiopharm 20:436-49. 2005
    ....
  15. ncbi Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model
    Wouter A P Breeman
    Department of Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
    Int J Cancer 104:376-9. 2003
    ..177)Lu-DOTA-tate showed anti-tumoral effects in both cases and significant survival in the PRRT-treated rats. (177)Lu-DOTA-tate is a very promising new treatment modality for SSR-positive tumors, including disseminated disease...
  16. ncbi The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity
    Wouter A P Breeman
    Department of Nuclear Medicine, Erasmus University Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 30:312-5. 2003
    ..After labelling [DOTA(0),Tyr(3)]octreotate with (177)Lu the addition of DTPA prior to intravenous administration of [(177)Lu-DOTA(0),Tyr(3)]octreotate is strongly recommended...
  17. doi Automated module radiolabeling of peptides and antibodies with gallium-68, lutetium-177 and iodine-131
    Mario De Decker
    Department of Nuclear Medicine, The University of Western Australia, Fremantle Hospital, Fremantle, Australia
    Cancer Biother Radiopharm 27:72-6. 2012
    ....
  18. ncbi Production of 177Lu at the new research reactor FRM-II: Irradiation yield of 176Lu(n,gamma)177Lu
    Z Dvorakova
    Institut für Radiochemie der Technischen Universität München, D 85748 Garching, Germany
    Appl Radiat Isot 66:147-51. 2008
    ..The comparison of theoretically calculated and experimentally determined yield for Lu176(n,gamma)Lu177 reaction is presented...
  19. doi Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC
    Maribel L Sierra
    Nuclear Medicine Division, European Institute of Oncology, Milan, Italy
    Cancer Biother Radiopharm 24:659-65. 2009
    ..Since lymphocytes express somatostatin receptors, the aim of this study was to evaluate lymphocytic toxicity after PRRT...
  20. doi The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable
    T W Barber
    Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria 3002, Australia
    Eur J Surg Oncol 38:64-71. 2012
    ....
  21. ncbi Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs
    Marion de Jong
    Department of Nuclear Medicine, Erasmus Medical College, Rotterdam, The Netherlands
    J Nucl Med 46:13S-7S. 2005
    ..Suitable radionuclides are (90)Y, a pure, high-energy beta-emitter (2.27 MeV), and (177)Lu, a medium-energy beta-emitter (0.5 MeV) with a low-abundance gamma...
  22. ncbi Fabrication and characterization of a 0.5-mm lutetium oxyorthosilicate detector array for high-resolution PET applications
    Jennifer R Stickel
    Department of Radiology, School of Medicine, University of California Davis Medical Center, Davis, California 95817, USA
    J Nucl Med 48:115-21. 2007
    ..Though there are other contributing factors, the spatial resolution in small-animal PET is still largely determined by the detector pixel dimensions...
  23. ncbi Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro
    Astrid Capello
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    Cancer Biother Radiopharm 18:761-8. 2003
    ..In conclusion, tyr3-octreotate labeled with 177Lu or 90Y is the most promising analog for PRRT...
  24. ncbi Lutetium oxyorthosilicate block detector readout by avalanche photodiode arrays for high resolution animal PET
    B J Pichler
    Department of Biomedical Engineering, University of California, Davis, CA, USA
    Phys Med Biol 49:4305-19. 2004
    ..The readout of densely packed, 10 x 10 lutetium oxyorthosilicate (LSO) block detectors (crystal size 2.0 x 2...
  25. ncbi Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study
    Benjamin S Halpern
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, UCLA David Geffen School of Medicine, Los Angeles, California 90095 6942, USA
    J Nucl Med 46:603-7. 2005
    High photon attenuation and scatter in obese patients affect image quality. The purpose of the current study was to optimize lutetium orthosilicate (LSO) PET image acquisition protocols in patients weighing > or =91 kg (200 lb).
  26. ncbi High-phasing-power lanthanide derivatives: taking advantage of ytterbium and lutetium for optimized anomalous diffraction experiments using synchrotron radiation
    E Girard
    Laboratoire de Cristallographie Macromoléculaire, Institut de Biologie Structurale J P Ebel CEA CNRS UJF, 41 rue Jules Horowitz, 38027 Grenoble Cedex 01, France
    Acta Crystallogr D Biol Crystallogr 59:1877-80. 2003
    Ytterbium and lutetium are well suited for optimized anomalous diffraction experiments using synchrotron radiation...
  27. ncbi Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors
    Andrea Frilling
    Department of General, Visceral and Transplantation Surgery, University Hospital Essen, Germany
    Surgery 140:968-76; discussion 976-7. 2006
    ..The aim of the study was to present clinical experience with (90)Y- and (177)Lu-DOTATOC therapy in the management of NET...
  28. ncbi Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen
    Shankar Vallabhajosula
    Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital Weill Medical College of Cornell University, 525 E 68th Street, STARR 221, New York, NY 10021, USA
    J Nucl Med 46:850-8. 2005
    ....
  29. ncbi Performance characteristics obtained for a new 3-dimensional lutetium oxyorthosilicate-based whole-body PET/CT scanner with the National Electrical Manufacturers Association NU 2-2001 standard
    Marco Brambilla
    Health Physics Department, Azienda Ospedaliera Maggiore della Carita, Novara, Italy
    J Nucl Med 46:2083-91. 2005
    This article reports the results of performance measurements obtained for the lutetium oxyorthosilicate (LSO)-based whole-body PET/CT scanner Biograph 16 HI-REZ with the National Electrical Manufacturers Association (NEMA) NU 2-2001 ..
  30. ncbi Preparation and preliminary biological evaluation of 177Lu-labelled hydroxyapatite as a promising agent for radiation synovectomy of small joints
    Sudipta Chakraborty
    Radiopharmaceuticals Division bRadiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Mumbai, India
    Nucl Med Commun 27:661-8. 2006
    b>Lutetium-(177)Lu) is considered to be a promising radionuclide for use in radiation synovectomy of small-sized joints owing to its favourable decay characteristics [t(1/2)=6.73 days, E(beta)(max)=0.49 MeV, E(gamma)=113 keV (6...
  31. ncbi In vivo evaluation of 177Lu- and 67/64Cu-labeled recombinant fragments of antibody chCE7 for radioimmunotherapy and PET imaging of L1-CAM-positive tumors
    Jürgen Grünberg
    Center for Radiopharmaceutical Science ETH PSI USZ, Paul Scherrer Institute, Villigen, Switzerland
    Clin Cancer Res 11:5112-20. 2005
    ....
  32. ncbi On the preparation of a therapeutic dose of 177Lu-labeled DOTA-TATE using indigenously produced 177Lu in medium flux reactor
    Tapas Das
    Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai 400085, India
    Appl Radiat Isot 65:301-8. 2007
    ..85 GBq) of 177Lu activity, thereby implying that in order to achieve a single patient dose of 150-200 mCi (5.55-7.40 GBq), 300-400 microg of the conjugate needs to be used...
  33. ncbi Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues
    Yubin Miao
    Department of Internal Medicine, University of Missouri Columbia, Columbia, MO 65211, USA
    Nucl Med Biol 33:723-33. 2006
    ....
  34. ncbi Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma
    Martijn van Essen
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 47:1599-606. 2006
    ..Here we present the effects of this therapy in a small number of patients with metastasized or inoperable paragangliomas, meningiomas, small cell lung carcinomas (SCLCs), and melanomas...
  35. ncbi Effects of treatment with (177)Lu-DOTA-Tyr(3)-octreotate on uptake of subsequent injection in carcinoid-bearing nude mice
    Peter Bernhardt
    Department of Radiation Physics, Sahlgrenska University Hospital, Goteborg, Sweden
    Cancer Biother Radiopharm 22:644-53. 2007
    ..The aim of this study was to analyze the effect therapeutic injections of (177)Lu-DOTA(0)-Tyr(3)]-octreotate (DOTATATE) had on the tumor uptake of a subsequent injection with (111)In-DOTATATE in GOT1-bearing nude mice...
  36. ncbi Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen
    Neil H Bander
    Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
    Semin Oncol 30:667-76. 2003
    ..Three phase I studies are in progress, two using the beta-emitting radiometals yttrium 90 and lutetium 177, and a third using a cytotoxin (DM1) linked to J591...
  37. ncbi Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49
    Subhash C Chauhan
    Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198, USA
    Eur J Nucl Med Mol Imaging 32:264-73. 2005
    b>Lutetium-177 (177Lu) is a radionuclide of interest for radioimmunoimaging (RII) and radioimmunotherapy (RIT) on account of its short half-life (161 h) and the ability to emit both beta and gamma radiation...
  38. ncbi Lutetium-177-labeled gastrin releasing peptide receptor binding analogs: a novel approach to radionuclide therapy
    S Panigone
    Bracco Imaging SpA, Milan, Italy
    Q J Nucl Med Mol Imaging 50:310-21. 2006
    ..This review covers the efforts currently underway to develop new and clinically promising GRP-receptor specific molecules labeled with imageable and therapeutic radionuclides...
  39. ncbi A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro
    Tapan Nayak
    Radiopharmaceutical Sciences Program, College of Pharmacy, University of New Mexico Health Sciences Center, Albuquerque, NM 87131 0001, USA
    Cancer Biother Radiopharm 20:52-7. 2005
    ..The somatostatin analog [DOTA(0)-Tyr(3)]-octreotide (DOTATOC) has been widely used to target somatostatin receptor expressing tumors for therapy using radionuclides such as (90)Y or (177)Lu...
  40. ncbi Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells
    Tapan K Nayak
    Radiopharmaceutical Sciences Program, College of Pharmacy, University of New Mexico, Albuquerque, NM 87131 0001, USA
    Nucl Med Biol 34:185-93. 2007
    ....
  41. ncbi [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells
    Mikael Persson
    Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Eur J Nucl Med Mol Imaging 32:1457-62. 2005
    ..The purpose of this study was to analyse whether pertuzumab retains HER-2 targeting capacity after labelling with the therapeutically interesting beta emitter (177)Lu and to make initial characterizations in vitro and in vivo...
  42. ncbi Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu
    Huma Mohsin
    Department of Chemistry, University of Missouri Columbia, Columbia, Missouri 65211, USA
    Bioconjug Chem 17:485-92. 2006
    ..When labeled with 149Pm, 166Ho, and 177Lu, MeO-DOTA-CC49 has potential for RIT of colorectal cancer and other carcinomas...
  43. ncbi Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein
    Donald J Buchsbaum
    Department of Radiation Oncology, University of Alabama at Birmingham, Alabama 35294 6832, USA
    Clin Cancer Res 11:8180-5. 2005
    ..This study examined a pretarget radioimmunotherapy strategy for treatment of an i.p. tumor model (LS174T)...
  44. ncbi Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors
    E P Krenning
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    J Endocrinol Invest 28:146-50. 2005
    ..Also, the development of therapy strategies with combinations of different radionuclides and or peptides is of interest as these strategies may provide an increase in therapeutic efficacy in the future...
  45. ncbi (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab
    Lars R Perk
    Department of Otolaryngology Head and Neck Surgery, VU University Medical Center, Amsterdam, The Netherlands
    J Nucl Med 46:1898-906. 2005
    ..Cetuximab was selected as a model mAb because it abundantly internalizes after binding to the epidermal growth factor receptor...
  46. ncbi Electron- and positron-emitting radiolanthanides for therapy: aspects of dosimetry and production
    Helena Uusijärvi
    Department of Radiation Physics, Goteborg University, Sahlgrenska University Hospital, Goteborg, Sweden
    J Nucl Med 47:807-14. 2006
    ..The aim of this work was to investigate the suitability of electron- and positron-emitting radiolanthanides for radionuclide therapy with reference to dosimetry and production possibilities...
  47. ncbi Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule
    Vladimir Tolmachev
    Affibody AB, Bromma, Sweden
    Cancer Res 67:2773-82. 2007
    ..Thus, fusion with ABD improved the in vivo biodistribution, and the results highlight (177)Lu-CHX-A''-DTPA-ABD-(Z(HER2:342))(2) as a candidate for treatment of disseminated tumors with a high level of HER2 expression...
  48. ncbi Evaluation of 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties
    Karin Knogler
    Center for Radiopharmaceutical Science ETH PSI USZ, Paul Scherrer Institute, CH 5232 Villigen, Switzerland
    Nucl Med Biol 33:883-9. 2006
    ....
  49. pmc Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice
    Christopher V Johnson
    Department of Veterinary Pathobiology, University of Missouri Columbia, Columbia, MO, Harry S Truman Memorial Veterans Hospital, Columbia, MO 65201 5275, USA
    Cancer Biother Radiopharm 21:155-66. 2006
    ....
  50. ncbi In vitro and in vivo evaluation of 177Lu- and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers
    Michael F Giblin
    Research Service, Harry S Truman Memorial Veterans Administration Hospital, Columbia, MO 65201, USA
    Nucl Med Biol 33:481-8. 2006
    ..These results demonstrate the ability of 177Lu- and 90Y-labeled ST(h) molecules to specifically target GC-C receptors expressed on T-84 human colon cancer cells...
  51. ncbi Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity
    Shankar Vallabhajosula
    Department of Radiology, Division of Nuclear Medicine, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York 10021, USA
    Clin Cancer Res 11:7195s-7200s. 2005
    ..Fractionated dose regimens may decrease myelotoxicity and increase greater total administered dose. We have studied the effect of two or three treatments of 177Lu-J591 and 90Y-J591 monoclonal antibodies (mAb) on myelotoxicity...
  52. ncbi Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC
    Christiane Wehrmann
    Department of Nuclear Medicine Center for P E T, Zentralklinik Bad Berka, Bad Berka, Germany
    Cancer Biother Radiopharm 22:406-16. 2007
    ..In this study, we compared the dosimetric parameter uptake, half-life (kinetics), and mean absorbed organ and tumor doses of (177)Lu DOTA-NOC and (177)Lu DOTA-TATE...
  53. ncbi 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo
    Rosana B Michel
    Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA
    Nucl Med Biol 32:269-78. 2005
    ..This conclusion, however, may not apply to therapy of macroscopic tumors...
  54. pmc Rational design and generation of a bimodal bifunctional ligand for antibody-targeted radiation cancer therapy
    Hyun Soon Chong
    Chemistry Division, Biological, Chemical, and Physical Sciences Department, Illinois Institute of Technology, Chicago, Illinois 60616, USA
    J Med Chem 51:118-25. 2008
    ..C-NETA rapidly binds both Lu(III) and Bi(III), and the respective metal complexes remain extremely stable in serum for 14 days. (177)Lu -C-NETA and (205/6)Bi -C-NETA possess an excellent or acceptable in vivo biodistribution profile...
  55. ncbi Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re
    Adrienne H Brouwers
    Department of Nuclear Medicine, University Medical Center Nijmegen, NL 6500 HB Nijmegen, The Netherlands
    J Nucl Med 45:327-37. 2004
    ....
  56. ncbi Radiolabelling of glucose-Tyr3-octreotate with 125I and analysis of its metabolism in rats: comparison with radiolabelled DOTA-Tyr3-octreotate
    Milos Petrik
    Department of Biophysics and Physical Chemistry, Faculty of Pharmacy, Charles University, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
    Anticancer Res 27:3941-6. 2007
    ..The radiochemical purity of radiolabelled peptides and the analyses of rat urine were determined by HPLC and/or ITLC-SG methods. Male Wistar rats were used in the elimination studies...
  57. ncbi Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma
    Ernst J Postema
    Department of Nuclear Medicine, UMC Nijmegen, Nijmegen, The Netherlands
    Cancer Biother Radiopharm 18:525-33. 2003
    ..The biodistribution of hLL2 labeled with (131)I, (186)Re, (177)Lu, and (88)Y was studied in nude mice with subcutaneous human lymphoma xenografts in order to determine the most suitable of these four radionuclides for RIT with hLL2...
  58. ncbi Anaerobic 90Y- and 177Lu-labeling of a DOTA-conjugated nonpeptide vitronectin receptor antagonist
    Shuang Liu
    Bristol Myers Squibb Medical Imaging, 331 Treble Cove Road, North Billerica, Massachusetts 01862, USA
    Bioconjug Chem 14:1030-7. 2003
    ..The anaerobic formulation described in this study is particularly useful for (90)Y- and (177)Lu-labeling of DOTA-conjugated small biomolecules, which are sensitive to the radiolytic degradation during radiolabeling...
  59. doi Target burn-up corrected specific activity of 177Lu produced via 176Lu(n, gamma) 177Lu nuclear reactions
    K P Zhernosekov
    Institut fur Radiochemie, Technischen Universitat Munchen, Garching, Germany
    Appl Radiat Isot 66:1218-20. 2008
    ..It is shown that (176)Lu burn-up has to be taken into account to estimate the (177)Lu specific activity related to the total mass or amount of lutetium in the system.
  60. doi Preparation and preliminary studies on 177Lu-labeled hydroxyapatite particles for possible use in the therapy of liver cancer
    Sudipta Chakraborty
    Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
    Nucl Med Biol 35:589-97. 2008
    ..Hydroxyapatite (HA) particles of 20-60 microm size range are chosen as the particulate carrier due to its excellent biocompatibility and ease of labeling with lanthanides...
  61. ncbi Aminocarboxylate complexes and octreotide complexes with no carrier added 177Lu, 166Ho and 149Pm
    Wen Ping Li
    Department of Chemistry, University of Missouri, Columbia, MO, USA
    Nucl Med Biol 30:241-51. 2003
    ..The biodistribution studies of the NCA complexes with DTPA, DOTA and DTPA-OCT showed that the in vitro model correctly predicted the in vivo stability of the radiolanthanide complexes, with Ln-DOTA > Ln-DTPA > Ln-DTPA-OCT...
  62. ncbi 177Lu labelled polyaminophosphonates as potential agents for bone pain palliation
    S Chakraborty
    Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
    Nucl Med Commun 23:67-74. 2002
    ..i.)) with rapid clearance from blood and minimum uptake in soft tissues. These studies reveal that 177Lu complexes with the synthesized ligands have a potential use in palliative treatment of painful bone metastasis...
  63. ncbi In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications
    Diane E Milenic
    Chemistry Section, Radiation Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Nucl Med Biol 29:431-42. 2002
    ..Based on these in vitro and in vivo studies, the CHX-A" DTPA ligand should be considered a suitable bifunctional chelate for the radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapy applications...
  64. ncbi Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice
    Michael R Lewis
    Department of Veterinary Medicine and Surgery, University of Missouri Columbia, Columbia, MO 65211, USA
    Nucl Med Biol 31:213-23. 2004
    ..2% ID/g), and (177)Lu (35.4% ID/g) peaked at 1-4 h. Rapid blood disappearance was accompanied by urinary excretion of 59-66% ID within 1 h. Biodistributions of these agents show promise for pretargeted radioimmunotherapy of cancer...
  65. ncbi [177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against glioma
    Asa Liljegren Sundberg
    Division of Biomedical Radiation Sciences, Uppsala University, Uppsala, Sweden
    Cancer Biother Radiopharm 19:195-204. 2004
    ..In conclusion, [177Lu]Bz-DTPA-EGF seems to be a promising candidate for locoregional treatment of glioblastoma due to its high binding affinity, low molecular weight, and ability to target EGFR in vivo...
  66. ncbi 177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation
    Tapas Das
    Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
    Appl Radiat Isot 57:177-84. 2002
    ..23%/g in femur and 5.23% in tibia at 3 h p. i.), rapid clearance from blood (no activity at 3 h p. i.) and minimum uptake in soft tissues...
  67. ncbi Standardisation and decay data of 177Lu and 188Re
    U Schötzig
    Physikalisch Technische Bundesanstalt, Braunschweig, Germany
    Appl Radiat Isot 55:89-96. 2001
    ..The half-lives were measured with ionization chambers, yielding T(1/2)(177Lu) = 6.646(5) d and T(1/2)(188Re) = 0.70848(9) d...
  68. ncbi A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu
    Mark W Konijnenberg
    Mallinckrodt Medical, Tyco Healthcare, Petten, The Netherlands
    J Nucl Med 45:1260-9. 2004
    ..The aim of this work was to develop a generalized computational model for internal dosimetry in rats...
  69. doi Synthesis, stabilization and formulation of [177Lu]Lu-AMBA, a systemic radiotherapeutic agent for Gastrin Releasing Peptide receptor positive tumors
    Jianqing Chen
    Bracco Research USA Inc, 305 College Road East, Princeton, NJ 08540, USA
    Appl Radiat Isot 66:497-505. 2008
    ..The method of stabilization should be useful for other methionine-containing peptide radiopharmaceuticals in diagnostic and therapeutic applications...
  70. ncbi Preparation and preliminary biological evaluation of a 177Lu labeled sanazole derivative for possible use in targeting tumor hypoxia
    Tapas Das
    Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai 400085, India
    Bioorg Med Chem 12:6077-84. 2004
    ..88%/g at 1h post-injection) with favorable tumor to blood (4.00 at 1h post-injection) and tumor to muscle (4.63 at 1h post-injection) ratios...
  71. doi Lanthanide(III) complexes of bis(phosphonate) monoamide analogues of DOTA: bone-seeking agents for imaging and therapy
    Tomas Vitha
    Biocatalysis and Organic Chemistry, Department of Biotechnology, Delft University of Technology, Julianalaan 136, Delft, The Netherlands
    J Med Chem 51:677-83. 2008
    ..1 and 11 s(-1) mM(-1), respectively. An in vivo gamma-ray imaging study showed that the (177)Lu complexes of 2a and 2b have a high affinity for bones, particularly for growth plates and teeth with a prolonged retention...
  72. ncbi Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I
    R Stein
    Garden State Cancer Center, Belleville NJ 07109, USA
    J Nucl Med 42:967-74. 2001
    ..With its radiophysical properties similar to those of (131)I, coupled with its facile and stable attachment to mAb, (177)Lu promises to be an alternative to (131)I, and a complement to (90)Y, in radioimmunotherapy...
  73. ncbi Tumour thrombus from follicular thyroid cancer detected by 18F-FDG-PET/CT
    Tamer Ozülker
    Hell J Nucl Med 12:66-7. 2009
  74. ncbi Ionic charge, radius, and potential control root/soil concentration ratios of fifty cationic elements in the organic horizon of a beech (Fagus sylvatica) forest podzol
    Germund Tyler
    Department of Ecology, Soil Plant Research, Ecology Building, SE 223 62 Lund, Sweden
    Sci Total Environ 329:231-9. 2004
    ..copper, dysprosium, erbium, europium, gallium, gadolinium, hafnium, mercury, holmium, indium, lanthanum, lithium, lutetium, niobium, neodymium, nickel, lead, praseodymium, rubidium, scandium, samarium, tin, terbium, thorium, titanium, ..
  75. ncbi Selective accumulation of light or heavy rare earth elements using gram-positive bacteria
    Takehiko Tsuruta
    Department of Applied Chemistry, Tohwa University 1 1 1, Chikushigaoka, Fukuoka 815 8510, Japan
    Colloids Surf B Biointerfaces 52:117-22. 2006
    ..S. albus can accumulate greater lutetium than other REEs from a solution containing yttrium and eight heavy REEs. On the other hand, A...
  76. ncbi Radiolabeled peptides in oncology: role in diagnosis and treatment
    Ronald E Weiner
    Department of Diagnostic Imaging and Therapeutics, University of Connecticut Health Center, Farmington, Connecticut 06030 2804, USA
    BioDrugs 19:145-63. 2005
    ..peptides (including (111)In-pentetreotide, Yttrium-90 [90Y]-DOTA-Phe1-Tyr3-octreotide, 90Y-DOTA-lanreotide, and Lutetium-177 [177Lu]-DOTA-octreotate) for the treatment of patients with neuroendocrine malignancy are in progress...
  77. ncbi Gateways to clinical trials
    M Bayes
    Prous Science, S A, 08080 Barcelona, Spain
    Methods Find Exp Clin Pharmacol 25:747-71. 2003
    ..lonafarnib, lotrafiban; Melagatran, melatonin, 2-methoxyestradiol, metreleptin, motexafin gadoliniu, motexafin lutetium; Natalizumab, nelarabine, NO-aspirin, NSC-683864; ONO-6126; Pemetrexed disodium, pexelizumab, pirfenidone, ..
  78. ncbi Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours
    Kjell Oberg
    Department of Endocrine Oncology, University Hospital, SE 751 85, Uppsala, Sweden
    Best Pract Res Clin Endocrinol Metab 19:265-76. 2005
    ..The most recent compound is (177)lutetium-DOTA-Tyr3-octreotate, which has been applied by the Rotterdam group and has been reported to give partial ..
  79. doi Reactions of aromatic N-heterocycles with d0fn-metal alkyl complexes supported by chelating diamide ligands
    Paula L Diaconescu
    Department of Chemistry and Biochemistry, University of California, Los Angeles, California 90095, USA
    Acc Chem Res 43:1352-63. 2010
    ..The comparison between yttrium and lutetium benzyl complexes supported by ferrocene- or pyridine-diamide ligands indicated that similar reactions occurred ..
  80. doi Lanthanide complexes of triethylenetetramine tetra-, penta-, and hexaacetamide ligands as paramagnetic chemical exchange-dependent saturation transfer contrast agents for magnetic resonance imaging: nona- versus decadentate coordination
    Dirk Burdinski
    Department of Biomolecular Engineering, Philips Research Europe, High Tech Campus 11, 5656 AE Eindhoven, The Netherlands
    Inorg Chem 48:6692-712. 2009
    ..This switch in coordination mode, which is caused by decreasing metal ion radii going from lanthanum to lutetium (lanthanide contraction), has no significant effect on the T(1)-relaxivity of these complexes...
  81. ncbi Photodynamic therapy with motexafin lutetium for rectal cancer: a preclinical model in the dog
    H M Ross
    Department of Surgery, Division of Colon and Rectal Surgery, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania 19096, USA
    J Surg Res 135:323-30. 2006
    ..This study evaluated the safety, tissue penetration of 730 nm light, normal tissue toxicity and surgical outcome in a dog model of rectal resection after motexafin lutetium-mediated photodynamic therapy.
  82. doi Rare-earth metal complexes supported by 1,omega-dithiaalkanediyl-bridged bis(phenolato) ligands: synthesis, structure, and heteroselective ring-opening polymerization of rac-lactide
    Haiyan Ma
    Institute of Inorganic Chemistry, RWTH Aachen University, Landoltweg 1, Aachen, Germany
    Inorg Chem 47:3328-39. 2008
    Monomeric yttrium and lutetium bis(phenolato) complexes [Ln(OSSO){N(SiHMe 2) 2}(THF)] (Ln = Y, Lu) were prepared from the reaction of silylamido complexes [Ln{N(SiHMe 2) 2} 3(THF) 2] with 1 equiv of tetradentate 1,omega-dithiaalkanediyl-..
  83. ncbi A count-rate model for PET scanners using pixelated Anger-logic detectors with different scintillators
    S Surti
    Department of Radiology, University of Pennsylvania, Philadelphia, 19104, USA
    Phys Med Biol 50:5697-715. 2005
    ..based on pixelated Anger-logic detectors using lanthanum bromide (LaBr(3)), gadolinium orthosilicate (GSO) and lutetium orthosilicate (LSO) scintillators...
  84. ncbi Highly sensitive chelating agents for histochemical staining of rare earth metals
    Y Sumi
    Department of Chemistry, St Marianna University School of Medicine, Sugao, Miyamae ku, Kawasaki 216 8511, Japan
    Histochem Cell Biol 112:179-82. 1999
    ..very small amounts of rare earth metals, particularly praseodymium, terbium, dysprosium, holmium, ytterbium, and lutetium. Differentiation of a target metal from interfering metals was achieved using masking agents, polyphosphates and ..
  85. ncbi Radiometals as payloads for radioimmunotherapy for lymphoma
    Gerald L DeNardo
    Radiodiagnosis and Therapy, Division of Hematology Oncology, University of California Davis Medical Center, Sacramento, USA
    Clin Lymphoma 5:S5-10. 2004
    ..b-emitting lanthanides like those of 90Y, lutetium 177, etc...
  86. ncbi High performance liquid chromatographic studies on lanthanides, uranium and thorium on amide modified reversed phase supports
    M Akhila Maheswari
    Department of Chemistry, Indian Institute of Technology, Chennai 600036, India
    Talanta 72:730-40. 2007
    ..Individual separations of heavier lanthanides, i.e., from gadolinium to lutetium also have been achieved using 4HHBA and B2EHM modified supports...
  87. doi Novel neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors
    Faisal Alshoukr
    INSERM, U773, Paris, France
    Bioconjug Chem 20:1602-10. 2009
    ..3 peptide is a promising candidate for imaging neurotensin receptor-positive tumors, such as pancreatic adenocarcinoma and invasive ductal breast cancer. Analogues carrying DOTA are being developed for yttrium-90 or lutetium-177 labeling.
  88. doi Pre-clinical PET/MR: technological advances and new perspectives in biomedical research
    Hans F Wehrl
    Department of Radiology, Laboratory for Preclinical Imaging and Imaging Technology of the Werner Siemens Foundation, University of Tubingen, Röntgenweg 13, 72076, Tubingen, Germany
    Eur J Nucl Med Mol Imaging 36:S56-68. 2009
    ..Especially in small-animal research, where high soft tissue contrast is required, and the scan time as well as radiation dose are critical factors, the combination of PET and MRI would be beneficial compared with PET/CT...
  89. ncbi Structure, stability, dynamics, high-field relaxivity and ternary-complex formation of a new tris(aquo) gadolinium complex
    Aline Nonat
    Laboratoire de Reconnaissance Ionique and Chimie de Coordination, Service de Chimie Inorganique et Biologique, Departement de Recherche Fondamentale sur la Matiere Condensee, CEA Grenoble, 17 rue des Martyrs, 38054 Grenoble, Cedex 09, France
    Chemistry 13:8489-506. 2007
    ..It can form 1:1 and 1:2 lanthanide/ligand complexes. The crystal structure of the bis(aquo) lutetium complex [Lu(dpaa)(H2O)2] has been determined by X-ray diffraction studies...
  90. pmc Micro insert: a prototype full-ring PET device for improving the image resolution of a small-animal PET scanner
    Heyu Wu
    Mallinckrodt Institute of Radiology, Washington University, St Louis, Missouri, USA
    J Nucl Med 49:1668-76. 2008
    ..A full-ring PET insert device should be able to enhance the image resolution of existing small-animal PET scanners...
  91. ncbi A feasibility study of a prototype PET insert device to convert a general-purpose animal PET scanner to higher resolution
    Heyu Wu
    Mallinckrodt Institute of Radiology, Washington University, St Louis, Missouri 63110, USA
    J Nucl Med 49:79-87. 2008
    ..We developed a prototype system to evaluate the feasibility of using a PET insert device to achieve higher resolution from a general-purpose animal PET scanner...
  92. ncbi Mixed d-f3 coordination complexes possessing improved near-infrared (NIR) lanthanide luminescent properties in aqueous solution
    Aline M Nonat
    School of Chemistry, Center for Synthesis and Chemical Biology, Trinity College Dublin, Dublin 2, Ireland
    Inorg Chem 49:8449-56. 2010
    ..ligand forms kinetically stable complexes, 1·Ln, with lanthanide ions such as Ln = ytterbium, neodymium, and lutetium (formed as a non-IR emitting reference compound), the synthesis and photophysical properties of which are ..
  93. ncbi Interaction between photodynamic therapy and BCG immunotherapy responsible for the reduced recurrence of treated mouse tumors
    M Korbelik
    Cancer Imaging Department, British Columbia Cancer Research Centre, 601 West 10th Avenue, Vancouver, B C, Canada V5Z 1L3
    Photochem Photobiol 73:403-9. 2001
    ..used: Photofrin, benzoporphyrin derivative, tetra(m-hydroxyphenyl)chlorin (foscan), mono-L-aspartylchlorin e6, lutetium texaphyrin or zinc phthalocyanine...
  94. doi Preparation of 177Lu-labeled oxine in lipiodol as a possible agent for therapy of hepatocellular carcinoma: a preliminary animal study
    Suresh Subramanian
    Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
    Cancer Biother Radiopharm 25:539-43. 2010
    ..Oxine or 8-hydroxyquinoline was labeled with (177)Lu obtained by neutron irradiation of natural lutetium. Under optimized conditions, the radiolabeled complex was obtained with yields >98% and adequate in vitro ..
  95. ncbi Development of a new bombesin analog radiolabeled with lutetium-177: in vivo evaluation of the biological properties in balb-C mice
    P B Pujatti
    Directory of Radiopharmacy, Nuclear and Energy Research Institute, IPEN CNEN, Sao Paulo
    Cell Mol Biol (Noisy-le-grand) 56:18-24. 2010
    In this work we describe the first results of radiolabeling with lutetium-177 (177Lu) and in vivo biodistribution and pharmacokinetics studies in normal Balb-c mice of a new bombesin analog (BEFG2)--DOTA-Phe-X-BBN(6-14), where X is a ..
  96. ncbi Photodynamic therapy in the canine prostate using motexafin lutetium
    R A Hsi
    Department of Radiation Oncology, Virginia Mason Medical Center, Seattle, Washington 98101, USA
    Clin Cancer Res 7:651-60. 2001
    ..the feasibility of comprehensive treatment of the canine prostate with photodynamic therapy (PDT) using motexafin lutetium (Lu-Tex) and to evaluate the toxicity and tissue effects associated with this treatment...
  97. ncbi Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy
    Jarod C Finlay
    Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA
    Photochem Photobiol 82:1270-8. 2006
    The in vivo fluorescence emission from human prostates was measured before and after motexafin lutetium (MLu)-mediated photodynamic therapy (PDT)...
  98. ncbi Optical properties of human prostate at 732 nm measured in mediated photodynamic therapy
    Timothy C Zhu
    Department of Radiation Oncology, University of Pennsylvania, 3400 Spruce Street 2 Donner, Philadelphia, PA 19104, USA
    Photochem Photobiol 81:96-105. 2005
    ..Measurements were made at 732 nm before and after motexafin lutetium (MLu)-mediated PDT in four quadrants...
  99. ncbi Spherical core-shell structured nanophosphors on the basis of europium-doped lutetium compounds
    Yu V Yermolayeva
    Scientific and Technological Corporation Institute for Single Crystals, NAS of Ukraine, Kharkov, Ukraine
    Nanotechnology 20:325601. 2009
    ..The possible reasons for such a phenomenon are also discussed...
  100. ncbi Optimizing injected dose in clinical PET by accurately modeling the counting-rate response functions specific to individual patient scans
    Charles C Watson
    Siemens Medical Solutions Molecular Imaging, Knoxville, Tennessee, USA
    J Nucl Med 46:1825-34. 2005
    ..We apply this technique to patient data and show how it can lead to improved clinical scanning protocols...
  101. ncbi MicroPET II: design, development and initial performance of an improved microPET scanner for small-animal imaging
    Yuan Chuan Tai
    UCLA, Crump Institute for Molecular Imaging, Los Angeles, CA 90095 1770, USA
    Phys Med Biol 48:1519-37. 2003
    ..0 cm and an axial length of 4.9 cm. Each detector module consists of a 14 x 14 array of lutetium oxyorthosilicate (LSO) crystals coupled to a multi-channel photomultiplier tube (MC-PMT) through a coherent ..

Research Grants74

  1. Low Cost Lu-based Scintillator Crystals for PET Scanners
    WESLEY HACKENBERGER; Fiscal Year: 2004
    ..Recent development of lutetium (Lu) based oxide crystals for a new generation of fast, high-resolution PET systems has made the situation even ..
  2. Production of High Specific Activity Lutetium-177
    Cathy Cutler; Fiscal Year: 2005
    A separation method will be tested and evaluated to determine the feasibility of providing no carrier added lutetium-177 (Lu-177) for use in radiotherapeutic applications...
  3. Optical Ceramic Hafnates: New Fast PET Scintillator
    Charles Brecher; Fiscal Year: 2006
    ..ceramic scintillator based on cerium-activated barium hamate (BaHfO3:-Ce), strontium hafnate (SrHfO3:-Ce), and lutetium hafnate (Lu2Hf2O7:Ce)...
  4. Time-of-flight PET for Improved whole-body imaging
    Joel S Karp; Fiscal Year: 2010
    ..We have developed PET detectors, both lanthanum bromide (LaBr3) and lutetium (yttrium) oxyorthosilicate (LYSO), which have excellent timing performance for TOF as well as sensitivity, energy ..
  5. Lanthanides as Novel Anti-Arthritic Agents
    Christopher Evans; Fiscal Year: 2004
    ..Gd3+), which lies in the middle of the series and has been widely used as a therapeutic agent in rats, and lutetium (Ln3+), the smallest lanthanide...
  6. Metallofullerene Nanoplatform for Imaging & Treatment
    Panos Fatouros; Fiscal Year: 2009
    ..The metallofullerenes can be affinity labeled for molecular targeting and can have lutetium (Lu) or terbium (Tb) substituted for Gd...
  7. Synthesis via Metal-Catalyzed and Cationic Cyclizations
    THOMAS STUART LIVINGHOUSE; Fiscal Year: 2010
    ..that a variety of non-metallocene complexes of the group 3 metals (particularly yttrium, scandium, lanthanum, lutetium and neodymium) are versatile and highly selective catalysts for the intramolecular hydroamination of carbon-..
  8. Synthesis via Metal-Catalyzed and Cationic Cyclizations
    THOMAS LIVINGHOUSE; Fiscal Year: 2007
    ..that a variety of non-metallocene complexes of the group 3 metals (particularly yttrium, scandium, lanthanum, lutetium and neodymium) are versatile and highly selective catalysts for the intramolecular hydroamination of carbon-..
  9. A Positron Emission Mammography/Tomography Biopsy Device
    RAYMOND RAYLMAN; Fiscal Year: 2006
    ..The choices of scintillator material (Lutetium Oxyorthosilicate) and detector pixel size were based on computer simulation studies and model observer studies...
  10. BIOMEDICAL APPLICATIONS OF EXPANDED PORPHYRINS
    Jonathan Sessler; Fiscal Year: 2004
    ..The second, to which the generic name motexafin lutetium has been assigned, is being tested in various formulations as a photosensitizer for use in (i) the photodynamic ..
  11. UWMC POSITRON EMISSION IMAGING ANIMAL FACILITY
    Thomas Lewellen; Fiscal Year: 2005
    ..The recent availability of new, multi-cathode photomultiplier tubes PMTs) and a reliable source of Lutetium Oxyorthosilicate (LSO) crystals has now made it possible to build these systems for general use...
  12. Multibeam Healing for Laser Micromachining in Manufacturing
    BIPIN SINGH; Fiscal Year: 2007
    ..of lasers makes them very attractive alternatives to traditional machining methods for brittle materials such as lutetium oxyorthosilicate (LSO) and gadolinium oxyorthosilciate (GSO) used in high-resolution medical imaging...
  13. Hybrid APD/ASIC Detector Module for Small Animal PET
    MICHAEL SQUILLANTE; Fiscal Year: 2002
    ..an application specific integrated circuit (ASIC) that is necessary to support new avalanche photodiode (APD) and lutetium orthosilicate (LSO) detector module designed for small-animal PET applications...
  14. APD BASED PET DETECTOR MODULES FOR BREAST IMAGING
    SIMON CHERRY; Fiscal Year: 2003
    ..The proposed detector module will consist of an array of small discrete lutetium oxyorthosilicate (LSO) scintillator elements, optically connected to two APD arrays at both ends...
  15. A High Performance PET and CT Tomograph
    David Townsend; Fiscal Year: 2004
    ..by designing and building a high performance PET scanner with integrated CT technology using the new scintillator lutetium oxy-orthosilicate (LSO)...
  16. Thick scintillation detector with continuous positioning & DOI capability for PET
    Suleman Surti; Fiscal Year: 2007
    ..Hence, thick continuous detectors have the potential to significantly impact the clinical imaging situation and the resultant patient treatment. ..
  17. A Time-of-Flight PET scanner for dedicated breast imaging
    Suleman Surti; Fiscal Year: 2010
    ..Hence, the development of a dedicated, TOF, breast scanner has the potential to significantly impact patient treatment for breast cancer. ..
  18. A High Resolution and High Sensitivity Dedicated Mouse Brain PET Scanner
    Yongfeng Yang; Fiscal Year: 2010
    ..During the fourth year of the current grant, we have successfully developed both rectangular and tapered lutetium oxyorthosilicate (LSO) arrays with crystal sizes down to 0...
  19. POSITION-SENSITIVE APD DETECTORS FOR SMALL ANIMAL PET
    Yongfeng Yang; Fiscal Year: 2007
    ....
  20. New Ligands for Radioimmunotherapy and MRI of Cancer
    Hyun Soon Chong; Fiscal Year: 2006
    ..The results of the proposed research will contribute to the development of better drugs for both MRI and RIT, which will greatly enhance clinical exploration of both modalities, and directly benefit cancer patients. ..